Market Overview

The global connected drug delivery devices market size is experiencing rapid growth as healthcare providers and patients increasingly adopt digital technologies to improve medication adherence, treatment monitoring, and disease management. The market reached USD 1,332.0 Million in 2025 and is projected to reach USD 8,520.4 Million by 2034, expanding at a CAGR of 22.21% during 2026–2034. North America dominated the market in 2025, accounting for 41.2% of the global market share.

The industry is being influenced by the rising prevalence of chronic diseases, an aging population, growing adoption of telemedicine, advancements in sensor technology, and increasing demand for remote patient monitoring. Integration with mobile applications, wireless connectivity, and digital healthcare platforms is also creating new opportunities for connected drug delivery device manufacturers.

Connected Drug Delivery Devices Market Snapshot

• Base Year: 2025

• Historical Period: 2020–2025

• Forecast Period: 2026–2034

• Market Size (2025): USD 1,332.0 Million

• Market Forecast (2034): USD 8,520.4 Million

• CAGR (2026–2034): 22.21%

• Leading Region: North America

• Dominant Product Segment: Integrated Connected Devices

• Leading Product Segment Share: 56.8% in 2025

• Dominant End-User Segment: Hospitals and Healthcare Providers

• Leading End-User Segment Share: 59.3% in 2025

• Dominant Technology Segment: Bluetooth

• Leading Technology Segment Share: 61.8% in 2025

North America accounted for 41.2% of the global connected drug delivery devices market in 2025, supported by increasing healthcare expenditure, advanced medical infrastructure, widespread adoption of connected healthcare technologies, and supportive regulatory frameworks.

Request a Sample Report for Detailed Evaluation: https://www.imarcgroup.com/connected-drug-delivery-devices-market/requestsample

What Is Driving Connected Drug Delivery Devices Market Growth?

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases, including diabetes, asthma, cardiovascular disorders, and other long-term health conditions, is increasing demand for advanced drug delivery devices that support accurate medication administration and effective treatment management. Patients with chronic illnesses often require regular medication, precise dosing, and continuous monitoring to maintain treatment adherence and improve health outcomes.

The growing adoption of connected drug delivery devices is addressing these needs by enabling real-time medication tracking, dosage recording, and automated reminders that help patients follow prescribed treatment regimens. These technologies are particularly beneficial for individuals requiring long-term therapies, as they can improve medication adherence, reduce dosing errors, and support more effective disease management.

Connected inhalers, smart injection sensors, and digitally integrated drug delivery systems provide valuable insights into medication usage and administration patterns. Healthcare professionals can leverage these data to identify missed doses, assess treatment adherence, detect potential issues, and develop more personalized treatment strategies. Consequently, the integration of digital health technologies into drug delivery devices is becoming increasingly important in chronic disease management.

Furthermore, the growing emphasis on preventive healthcare, patient-centric treatment, and remote patient monitoring is encouraging healthcare providers and drug delivery device manufacturers to invest in connected and intelligent delivery solutions. These developments are expected to support innovation across the connected drug delivery device market, as manufacturers focus on improving treatment efficiency, enhancing patient engagement, and delivering more effective long-term healthcare solutions.

Growing Demand for Medication Adherence and Remote Monitoring

Medication non-adherence remains an important challenge in chronic disease management. Missed doses, incorrect administration, and inconsistent medication schedules can reduce treatment effectiveness and increase the risk of complications.

Connected drug delivery devices are helping address these challenges through features such as automated reminders, dosage tracking, wireless data transmission, and real-time feedback. These capabilities provide patients with greater visibility into their medication routines while allowing healthcare professionals to monitor treatment patterns more effectively.

Remote monitoring is particularly useful for patients receiving care at home, where regular in-person supervision may not always be practical. Connected devices can transmit relevant medication information to compatible applications and healthcare platforms, supporting more informed treatment decisions.

The increasing emphasis on patient-centered healthcare, improved treatment adherence, and reduced avoidable hospital visits is creating favorable conditions for the expansion of connected drug delivery technologies.

Technological Advancements and Digital Healthcare Integration

Advancements in sensor technology, Bluetooth connectivity, mobile applications, and digital health platforms are transforming the connected drug delivery devices market.

Modern devices can record information such as dosage, administration time, device usage, and medication adherence. Depending on the product, they can also provide feedback that helps patients improve their medication routines and supports healthcare professionals in evaluating treatment progress.

Integration with smartphones and connected healthcare systems is improving accessibility and convenience. Patients can receive reminders and review medication records, while healthcare providers can use available data to support treatment adjustments and remote consultations.

The integration of connected drug delivery devices with telemedicine platforms is also creating opportunities for more coordinated care. As healthcare systems increasingly adopt digital solutions, manufacturers are investing in products that combine reliable medication delivery with connectivity, data collection, and patient engagement features.

Expansion of Telemedicine and Home-Based Healthcare

The expansion of telemedicine is supporting demand for connected drug delivery devices by enabling healthcare providers to monitor patients beyond traditional clinical settings.

The supplied market data indicates that the global telemedicine market reached USD 74.7 Billion in 2023. Telehealth platforms allow patients to consult healthcare professionals remotely, improving convenience and access to care.

Connected drug delivery devices complement these services by providing information about medication usage, dosage timing, and treatment adherence. This information can help healthcare professionals evaluate patient progress and identify situations that may require additional support.

The COVID-19 pandemic accelerated interest in remote healthcare solutions as patients and providers sought ways to maintain treatment continuity while reducing unnecessary visits to healthcare facilities. It also increased attention to home-based medication management and digital health technologies.

Although adoption patterns vary across healthcare systems, the continued development of telemedicine infrastructure and remote monitoring capabilities is creating opportunities for connected drug delivery device manufacturers.

Connected Drug Delivery Devices Market Trends to Watch

Three major trends are shaping the future of the global connected drug delivery devices industry.

Growing aging population: Older adults are more likely to experience chronic conditions that require consistent medication management. Connected devices can simplify treatment routines through reminders, dosage tracking, and remote monitoring, supporting greater independence and continuity of care.

Rising prevalence of chronic obstructive pulmonary disease (COPD): COPD and other respiratory conditions require effective medication delivery and consistent treatment adherence. Connected inhalers can help record usage, provide reminders, and offer feedback on inhaler technique, supporting better management of respiratory illnesses.

Expansion of telemedicine: The increasing adoption of virtual consultations and remote patient monitoring is encouraging the integration of connected drug delivery devices with digital healthcare platforms. These systems can provide useful medication information that supports treatment reviews and personalized care.

The aging population is an important factor behind these developments. According to the World Health Organization (WHO), the number of people aged 60 and older is projected to reach 2.1 Billion by 2050. This demographic shift is expected to increase demand for healthcare solutions that simplify medication management and support long-term care.

Respiratory disease management is another important area of opportunity. Connected inhalers can help patients and healthcare professionals understand medication usage patterns, identify missed doses, and monitor adherence. These features may support timely interventions and more informed treatment management.

Meanwhile, the continued integration of connected devices with telehealth services is helping healthcare providers develop more coordinated digital care models. By combining medication information with remote consultations, these solutions can improve visibility into treatment routines and support ongoing patient engagement.

Connected Drug Delivery Devices Market Segmentation

The global connected drug delivery devices market is analyzed by product, end user, and technology. Each segment reflects different requirements for medication delivery, monitoring, and connectivity across healthcare environments.

By Product

• Connected Sensors

  • Connected Inhaler Sensors

  • Connectable Injection Sensors

• Integrated Connected Devices

  • Connected Inhalation Devices

  • Connected Injection Devices

Integrated connected devices dominated the product segment in 2025, accounting for approximately 56.8% of the market. Their leading position is supported by the ability to combine medication delivery with monitoring and connectivity features in a unified system.

Connected inhalation devices and connected injection devices can record medication usage, dosage timing, and other relevant treatment information. These capabilities help patients follow prescribed regimens while providing healthcare professionals with information that can support treatment evaluation.

Connected inhalation devices are particularly relevant for patients managing respiratory conditions, as they can help monitor usage frequency and provide feedback on medication administration. Connected injection devices can record injection-related information, including dosage and timing, depending on the product's capabilities.

The integration of sensors, wireless connectivity, and digital applications also supports remote monitoring and patient engagement. By combining medication delivery with data collection, integrated devices can simplify treatment management and help healthcare providers identify potential adherence challenges.

Connected sensors represent another important product category. These devices can be attached to compatible drug delivery systems to add connectivity and monitoring capabilities without necessarily replacing the underlying medication delivery device.

Continued advances in sensor design, data integration, and device interoperability are expected to create opportunities across both connected sensors and integrated connected devices.

By End User

• Hospitals and Healthcare Providers

• Homecare

Hospitals and healthcare providers represented the largest end-user segment in 2025, accounting for approximately 59.3% of the market. Their leading position reflects the need for accurate medication management, improved treatment monitoring, and better patient outcomes across clinical settings.

Healthcare institutions increasingly use digital technologies to support medication administration, monitor patient progress, and improve treatment coordination. Connected drug delivery devices can provide information that helps clinicians evaluate medication adherence and identify potential issues during ongoing treatment.

The growing prevalence of diabetes, asthma, cardiovascular conditions, and other chronic diseases is strengthening demand for connected solutions in hospitals and healthcare facilities. These technologies can also complement remote monitoring programs by allowing relevant medication information to be shared beyond clinical environments.

Connected devices can support clinical decision-making by making medication usage data more accessible. However, their usefulness depends on appropriate integration with healthcare workflows, compatible systems, and suitable data management practices.

The homecare segment is also gaining importance as healthcare systems increasingly support treatment outside hospitals. Connected drug delivery devices can help patients manage medication schedules independently while allowing caregivers and healthcare professionals to monitor adherence where appropriate.

As healthcare delivery models continue to evolve, both clinical and homecare settings offer opportunities for technologies that improve medication management and patient engagement.

By Technology

• Bluetooth

• NFC

• Other Technologies

Bluetooth dominated the technology segment in 2025, accounting for approximately 61.8% of the market. Its leading position is supported by low power consumption, broad compatibility, and the ability to transmit medication-related information wirelessly to compatible devices.

Bluetooth connectivity enables connected inhalers, injection sensors, and other drug delivery systems to communicate with smartphones, tablets, and compatible healthcare platforms. This allows medication usage information to be recorded and reviewed without requiring continuous manual data entry.

Low power requirements are particularly useful for compact medical devices that need to operate over extended periods. Bluetooth can also support convenient integration with existing digital health applications, helping patients and healthcare professionals access relevant medication information.

Near-field communication (NFC) offers another connectivity option for compatible devices, particularly where short-range communication is appropriate. Other technologies may also be used depending on device requirements, connectivity needs, and intended healthcare applications.

As manufacturers continue to develop connected medication management solutions, interoperability, data security, power efficiency, and ease of use will remain important considerations in technology selection.

Regional Connected Drug Delivery Devices Market Outlook

North America

North America accounted for 41.2% of the global connected drug delivery devices market in 2025, making it the leading regional market. Growth is supported by advanced healthcare infrastructure, high healthcare expenditure, the adoption of digital health technologies, and the presence of established pharmaceutical and medical device companies.

The region benefits from investments in research and development, technological innovation, and healthcare delivery systems that increasingly incorporate remote monitoring and digital patient management.

According to information published by the Centers for Medicare & Medicaid Services, U.S. healthcare expenditure increased by 4.1% in 2022, reaching USD 4.5 Trillion, or USD 13,493 per person. This level of expenditure reflects the scale of the U.S. healthcare system and the importance of improving care delivery and treatment management.

Connected drug delivery devices can support these objectives by helping patients adhere to prescribed medication schedules and providing healthcare professionals with information about treatment usage.

Supportive regulatory frameworks and the development of digital health reimbursement models are also contributing to the adoption of connected medical technologies. Continued investment in connected devices and patient monitoring solutions is expected to create further opportunities across North America.

Asia Pacific

Asia Pacific represents an important opportunity for the connected drug delivery devices market, supported by the expansion of digital healthcare, growing telemedicine adoption, and increasing demand for chronic disease management.

China, India, Japan, South Korea, Australia, and Indonesia are among the key markets contributing to regional healthcare technology development. Rising smartphone adoption, improvements in healthcare infrastructure, and growing interest in remote patient monitoring are supporting demand for connected healthcare solutions.

According to the supplied report, India's digital healthcare segment was projected to grow from USD 2.7 Billion in 2022 to USD 37 Billion by 2030. This development highlights the potential for digital platforms to expand access to healthcare services and support connected medication management.

Connected drug delivery devices can complement these developments by enabling medication reminders, usage tracking, and information sharing between patients and healthcare professionals. Their integration with telemedicine platforms may be particularly valuable in areas where digital healthcare can improve access to ongoing care.

The region's large population and growing need for chronic disease management are creating opportunities for manufacturers to develop accessible, easy-to-use, and cost-effective connected solutions.

Europe

Europe's connected drug delivery devices market is supported by an aging population, established healthcare systems, and growing interest in digital patient management.

Older adults frequently require ongoing treatment for chronic conditions, making medication adherence and consistent monitoring important aspects of healthcare delivery. Connected devices can help simplify medication schedules through reminders, dosage records, and compatible monitoring applications.

The supplied report indicates that approximately one in five Europeans is aged 65 or older, with the proportion projected to approach 30% by 2050. This demographic shift is increasing the importance of technologies that support long-term care and independent living.

Connected drug delivery devices can help patients manage treatment routines while allowing caregivers and healthcare professionals to review medication information where appropriate. These capabilities may support continuity of care and help identify potential adherence issues.

The region's emphasis on healthcare quality, medical technology innovation, and digital health integration is also creating opportunities for manufacturers developing connected inhalers, injection systems, and other medication monitoring solutions.

Latin America

Latin America's connected drug delivery devices market is influenced by the growing need for chronic disease management, particularly for respiratory conditions such as chronic obstructive pulmonary disease.

The supplied report cites Brazilian data indicating that COPD was mentioned as a cause of death in 1,132,968 deaths among 22,663,091 total deaths recorded between 2000 and 2019.

Connected drug delivery devices can support respiratory disease management by recording inhaler usage, providing reminders, and helping patients monitor their treatment routines. These capabilities can also provide healthcare professionals with additional information about medication adherence.

Remote monitoring may be useful for patients who face challenges accessing frequent in-person consultations. When integrated with suitable healthcare services, connected devices can support ongoing treatment management and help clinicians identify situations requiring further assessment.

As digital health infrastructure develops across the region, connected drug delivery technologies may offer opportunities to improve medication management in both clinical and homecare environments.

Middle East and Africa

The Middle East and Africa region presents opportunities for connected drug delivery devices as healthcare infrastructure expands and providers increasingly explore digital technologies to improve patient care.

Investment in hospitals, clinics, healthcare professionals, and digital health systems is creating a foundation for the adoption of connected medical devices. These technologies can support medication tracking, treatment monitoring, and more coordinated patient management.

According to Dubai Healthcare City Authority data cited in the supplied report, Dubai had 4,482 private medical facilities and 55,208 licensed healthcare professionals in 2022. The report also indicated projected growth in healthcare facilities and licensed professionals during 2023.

Expanding healthcare capacity can create opportunities for connected drug delivery systems that help improve medication management and provide relevant data to healthcare teams.

The region's development of digital healthcare services and increased focus on patient-centered treatment may further support adoption. However, market development will depend on factors including infrastructure, affordability, regulatory requirements, and integration with existing healthcare systems.

Competitive Landscape

Companies in the connected drug delivery devices market are focusing on technological innovation, strategic partnerships, regulatory approvals, and integration with digital healthcare platforms to strengthen their competitive positions.

Manufacturers are investing in advanced sensors, wireless connectivity, real-time tracking, data analytics, and mobile application compatibility to improve medication adherence and patient engagement. These developments are helping companies expand the functionality of inhalers, injection systems, and other connected medication delivery products.

Regulatory approvals remain important for commercial adoption, particularly where connected technologies are integrated into medical devices used for chronic disease management. Companies are also collaborating with pharmaceutical manufacturers, healthcare providers, and technology firms to improve device compatibility and develop integrated digital treatment solutions.

In 2024, Medtronic announced that its Simplera continuous glucose monitor received FDA approval. The company also announced a global collaboration with Abbott to integrate Abbott's continuous glucose monitoring technology with Medtronic's intelligent insulin delivery systems. These developments reflect broader efforts to improve diabetes management through connected medical technologies.

Major companies identified in the global connected drug delivery devices market include:

• Adherium Ltd.

• BIOCORP Production

• Cohero Health Inc. (AptarGroup Inc.)

• Elcam Medical ACS Ltd.

• Findair Sp. z o.o.

• Merck KGaA

• Phillips Medisize (Molex LLC)

• Propeller Health (ResMed Inc.)

• Teva Pharmaceutical Industries Ltd.

• West Pharmaceutical Services Inc.

Recent Industry Developments

October 2024: Modivcare Inc. partnered with Tenovi to introduce Adherium's Hailie smart inhalers through its subsidiaries, VRI and Higi Care. The collaboration aims to improve care for patients with chronic respiratory conditions by leveraging connected drug delivery technology.

September 2024: SHL Medical launched Elexy, an electromechanical drug delivery system designed for connected medication management. Featuring cellular and Bluetooth connectivity, the device supports data collection related to drug usage, device performance, and container information.

June 2024: Aptar Digital Health partnered with SHL Medical to enhance connected drug delivery systems. The collaboration combines Aptar's software expertise with SHL Medical's autoinjectors and pen injectors to develop improved solutions for injectable therapies.

May 2024: Adherium Limited announced that AstraZeneca had selected its Hailie Smartinhaler platform for a clinical trial. The contract was valued at USD 1.1 Million over three years, supporting the use of connected respiratory monitoring technology in clinical research.

Where Are the Biggest Connected Drug Delivery Devices Market Opportunities?

The global connected drug delivery devices industry presents opportunities across several areas:

• Chronic disease management: Connected inhalers and injection systems can support medication adherence and treatment monitoring for patients with long-term conditions.

• Remote patient monitoring: Digital connectivity can help healthcare professionals access medication usage information beyond traditional clinical settings.

• Homecare solutions: Connected devices can support patients managing treatment independently while improving visibility into medication routines.

• Telemedicine integration: Compatibility with digital healthcare platforms can support more coordinated consultations and ongoing treatment management.

• Aging population: Easy-to-use connected devices can help older adults manage complex medication schedules and maintain independence.

• Sensor and connectivity innovation: Improvements in sensors, Bluetooth, and other communication technologies can enhance device functionality and convenience.

• Integrated connected devices: Combining medication delivery and monitoring in a single system can simplify treatment management and patient engagement.

• Respiratory care technologies: Connected inhalers can support adherence monitoring and provide feedback for patients managing asthma and COPD.

• Diabetes management: Connected injection devices can help record dosage information and support coordinated diabetes care.

• Healthcare provider partnerships: Collaboration with hospitals, pharmaceutical companies, and telehealth providers can improve device integration and adoption.

These opportunities are particularly relevant as healthcare systems increasingly emphasize connected care, treatment adherence, and data-driven patient management. Companies that develop reliable, user-friendly, and interoperable devices may be well positioned to address the evolving needs of patients and healthcare professionals.

Get Detailed Connected Drug Delivery Devices Market Intelligence

The headline market figures provide a useful overview of the industry's direction, but businesses evaluating market entry, product development, competitive positioning, or investment opportunities may require more detailed market intelligence.

A comprehensive connected drug delivery devices market report can help businesses assess:

• Market size and growth forecasts

• Product-type segmentation

• Connected sensor and integrated device analysis

• End-user market assessment

• Technology segmentation

• Regional and country-level market performance

• Market drivers and emerging trends

• Competitive landscape and key company profiles

• Regulatory developments and technological innovation

• Digital healthcare and telemedicine opportunities

• Recent industry developments

Detailed market insights can support strategic decisions involving product innovation, research and development, commercial expansion, and partnerships across the connected healthcare ecosystem.

Request a Sample Report: https://www.imarcgroup.com/connected-drug-delivery-devices-market/requestsample

Connected Drug Delivery Devices Market FAQs

What is the current size of the global connected drug delivery devices market?

The global connected drug delivery devices market reached USD 1,332.0 Million in 2025 and is projected to reach USD 8,520.4 Million by 2034.

What is the expected CAGR of the connected drug delivery devices market?

The global connected drug delivery devices market is projected to expand at a CAGR of 22.21% during 2026–2034.

Which region leads the connected drug delivery devices market?

North America led the global market in 2025, accounting for 41.2% of the market share. Its advanced healthcare infrastructure, high healthcare expenditure, and adoption of connected medical technologies support its leading position.

Which product segment dominates the connected drug delivery devices market?

Integrated connected devices represented the largest product segment in 2025, accounting for approximately 56.8% of the market. Their combination of medication delivery, monitoring, and connectivity features supports their adoption.

Which end-user segment holds the largest market share?

Hospitals and healthcare providers accounted for approximately 59.3% of the market in 2025, driven by demand for improved medication management, patient monitoring, and treatment outcomes.

Which technology dominates the connected drug delivery devices market?

Bluetooth led the technology segment in 2025, accounting for approximately 61.8% of the market. Its low power consumption, broad compatibility, and wireless data transmission capabilities support its widespread use.

What are the major trends in the connected drug delivery devices market?

Key trends include the growing aging population, rising prevalence of chronic diseases, increasing adoption of telemedicine, advancements in sensor technology, remote patient monitoring, and integration with digital healthcare platforms.

Who are the major companies in the connected drug delivery devices market?

Major companies include Adherium Ltd., BIOCORP Production, Cohero Health Inc., Elcam Medical ACS Ltd., Findair Sp. z o.o., Merck KGaA, Phillips Medisize, Propeller Health, Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services Inc.

Conclusion

The global connected drug delivery devices market is evolving rapidly as healthcare providers and patients increasingly adopt digital solutions for medication adherence, remote monitoring, and chronic disease management. Valued at USD 1,332.0 Million in 2025, the market is projected to reach USD 8,520.4 Million by 2034, registering a CAGR of 22.21% during 2026–2034.

Growth opportunities are emerging across integrated connected devices, connected sensors, Bluetooth-enabled systems, homecare solutions, and digital healthcare integration. North America maintains its leading position, while the expansion of telemedicine and healthcare infrastructure is creating opportunities across other regions.

Companies that invest in reliable device connectivity, sensor innovation, regulatory compliance, and patient-centered digital solutions can strengthen their competitive positioning in the evolving connected drug delivery devices industry.

About the Author

IMARC Group is a global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multidisciplinary team of industry experts, IMARC delivers market intelligence across sectors including healthcare, energy and mining, construction and manufacturing, automotive, chemicals and materials, and more.

Media & Sales Contact

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104